Literature DB >> 16940714

No benefit of hemodiafiltration over hemodialysis in lowering elevated levels of asymmetric dimethylarginine in ESRD patients.

Marta Kalousová1, Jan T Kielstein, Magdaléna Hodková, Tomás Zima, Sylvie Dusilová-Sulková, Jens Martens-Lobenhoffer, Stefanie M Bode-Boger.   

Abstract

BACKGROUND: It has been suggested that hemodiafiltration (HDF) is more efficient than hemodialysis (HD) in lowering plasma levels of the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine (ADMA), which is a strong and independent predictor of overall mortality in ESRD patients. METHODS/PATIENTS: Twenty ESRD patients (11 women) were studied during both a single online HDF session and a single HD session. In each patient, ADMA, L-arginine, SDMA, beta(2)-microglobulin and urea were measured at several time points.
RESULTS: Although HDF was clearly superior to HD in decreasing plasma beta(2)-microglobulin, there was no difference in the elimination characteristics of ADMA. However, HDF but not HD eliminated the nitric oxide synthase substrate L-arginine, making HD superior in increasing the L-arginine/ADMA ratio.
CONCLUSION: Neither HD nor HDF sufficiently removes the putative uremic toxin ADMA. The clinical significance of HD better improving the L-arginine/ADMA ratio (parameter of NO production) as compared to HDF needs to be determined.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16940714     DOI: 10.1159/000095360

Source DB:  PubMed          Journal:  Blood Purif        ISSN: 0253-5068            Impact factor:   2.614


  9 in total

Review 1.  Normal and pathologic concentrations of uremic toxins.

Authors:  Flore Duranton; Gerald Cohen; Rita De Smet; Mariano Rodriguez; Joachim Jankowski; Raymond Vanholder; Angel Argiles
Journal:  J Am Soc Nephrol       Date:  2012-05-24       Impact factor: 10.121

2.  Symmetric dimethylarginine as a proinflammatory agent in chronic kidney disease.

Authors:  Eva Schepers; Daniela V Barreto; Sophie Liabeuf; Griet Glorieux; Sunny Eloot; Fellype C Barreto; Ziad Massy; Raymond Vanholder
Journal:  Clin J Am Soc Nephrol       Date:  2011-08-04       Impact factor: 8.237

Review 3.  The role of asymmetric and symmetric dimethylarginines in renal disease.

Authors:  Edzard Schwedhelm; Rainer H Böger
Journal:  Nat Rev Nephrol       Date:  2011-03-29       Impact factor: 28.314

4.  Reference intervals for plasma L-arginine and the L-arginine:asymmetric dimethylarginine ratio in the Framingham Offspring Cohort.

Authors:  Nicole Lüneburg; Vanessa Xanthakis; Edzard Schwedhelm; Lisa M Sullivan; Renke Maas; Maike Anderssohn; Ulrich Riederer; Nicole L Glazer; Ramachandran S Vasan; Rainer H Böger
Journal:  J Nutr       Date:  2011-10-26       Impact factor: 4.798

Review 5.  Asymmetrical dimethylarginine in renal disease: limits of variation or variation limits? A systematic review.

Authors:  Johannes Jacobi; Philip S Tsao
Journal:  Am J Nephrol       Date:  2007-10-24       Impact factor: 3.754

Review 6.  Endothelial Dysfunction in Chronic Kidney Disease, from Biology to Clinical Outcomes: A 2020 Update.

Authors:  Stefanos Roumeliotis; Francesca Mallamaci; Carmine Zoccali
Journal:  J Clin Med       Date:  2020-07-23       Impact factor: 4.241

7.  Asymmetric dimethylarginine compartmental behavior during high-flux hemodialysis.

Authors:  Qiuna Du; Jiayuan Gao; Renhua Lu; Yun Jin; Yanfang Zou; Chen Yu; Yucheng Yan
Journal:  Ren Fail       Date:  2020-11       Impact factor: 2.606

8.  Comparison of toxin removal outcomes in online hemodiafiltration and intra-dialytic exercise in high-flux hemodialysis: a prospective randomized open-label clinical study protocol.

Authors:  Vaibhav Maheshwari; Lakshminarayanan Samavedham; Gade Pandu Rangaiah; Yijun Loy; Lieng Hsi Ling; Sunil Sethi; Titus Lau Wai Leong
Journal:  BMC Nephrol       Date:  2012-11-23       Impact factor: 2.388

9.  Determination of Asymmetric and Symmetric Dimethylarginine in Serum from Patients with Chronic Kidney Disease: UPLC-MS/MS versus ELISA.

Authors:  Jente Boelaert; Eva Schepers; Griet Glorieux; Sunny Eloot; Raymond Vanholder; Frédéric Lynen
Journal:  Toxins (Basel)       Date:  2016-05-13       Impact factor: 4.546

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.